Plain-English translation of NCT06963034 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help reduce the behavioral and psychological symptoms of schizophrenia better than a placebo (inactive pill). You would participate while staying in a hospital for 5 weeks, receiving either the new medication or placebo once daily by mouth. The researchers want to understand whether this treatment is safe and effective for people experiencing an acute worsening of schizophrenia symptoms.
Schizophrenia can cause severe symptoms that sometimes require hospitalization, and doctors need better treatment options to help people recover during these crises. This medication is being studied to see if it can offer patients relief from these difficult symptoms more effectively than current approaches.
You likely qualify if…
You likely don't qualify if…
You would be admitted to a hospital for 5 weeks and live there during the entire study. Each day, you would take either the new medication or a placebo pill by mouth once daily. Your doctors and nurses would monitor your symptoms, overall health, and how well you tolerate the treatment throughout your stay. Most people in this type of study also have regular check-ins to assess how you're doing and track any side effects.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
United States